...reducing urge urinary incontinence episodes and urgency episodes vs. placebo. Detailed data were not disclosed. Velicept Therapeutics Inc....
...Overactive Bladder Data" ). Vibegron and Myrbetriq are both ADRB3 agonists. Despite availability of treatments, Velicept...
...the potential for best-in-class efficacy and improved safety for patients with OAB." Brian Moy, Assistant Editor solabegron (GW427353) Velicept Therapeutics Inc. Adrenergic...

...investors CDK, Fountain Healthcare, Longitude Venture Partners and Becker Ventures also participated. Becker Ventures is Velicept's...
...adrenergic receptor β 3 (ADRB3) agonist, to treat overactive bladder, and conduct Phase III-enabling activities. Velicept...
...round. (see "Velicept Raises First Tranche of $21M Series B" ). Velicept Therapeutics Inc., Malvern, Pa. Shannon Lehnbeuter solabegron (GW427353) Velicept Therapeutics Inc. Adrenergic...

...2015-12-01 Type: Venture financing Raised: Not disclosed Investors: Caxton Alternative Management; Longitude Capital Management Note: Velicept...

...planned $21 million series B round of funding led by CAM Capital and Longitude Capital. Velicept...
...to treat overactive bladder. Velicept did not respond to inquiries. Biopharma management company NeXeption formed Velicept...
...plc (LSE:GSK, NYSE:GSK) in 2011. NeXeption's Steve Tullman is Velicept's chairman. The board also includes Velicept...

...Velicept will merge with AltheRx, and the surviving company will retain Velicept’s name and focus on...
...further details. The deal is slated to close by September. AltheRx Pharmaceuticals , Exton, Pa. Velicept Therapeutics Inc....